ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Genmab AS

Genmab AS (GMAB)

19,67
-0,14
(-0,71%)
Fermé 01 Février 10:00PM
19,67
0,00
(0,00%)
Après les heures de négociation: 12:10AM

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

Dernier
19,67
Prix Achat
18,26
Prix Vente
22,42
Volume échangé
1 321 025
19,61 Fourchette du Jour 19,97
0,00 Plage de 52 semaines 0,00
Cap du marché
Clôture Veille
19,81
Ouverture
19,78
Dernière Transaction
25
@
19.98
Dernière heure de transaction
Volume financier
US$ 26 162 429
VWAP
19,8046
Volume moyen (3 m)
-
Actions en circulation
660 745 350
Rendement du Dividende
-
Ratio Cours sur Bénéfices
29,98
Bénéfice par action (BPA)
6,59
Chiffre d'affairess
16,47B
Bénéfice net
4,35B

À propos de Genmab AS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the stan... Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered wth Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications. Show more

Secteur
Biological Pds,ex Diagnstics
Industrie
Biogenetic (human)
Site Web
Siège social
Copenhagen, Dnk
Fondé
2000
Genmab AS est coté dans le secteur Biological Pds,ex Diagnstics de la NASDAQ avec le ticker GMAB. Le dernier cours de clôture d'Genmab AS était de US$19,81. Au cours de la dernière année, les actions de Genmab AS ont été négociées dans une fourchette de prix de US$ 0,00 à US$ 0,00.

Genmab AS compte actuellement 660 745 350 actions en circulation. La capitalisation boursière d'Genmab AS est de US$13,09 milliard. Genmab AS a un ratio cours/bénéfice (ratio PE) de 29.98.

GMAB Dernières nouvelles

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Results from Arm 1 of the EPCORE® NHL-2 trial show treatment with epcoritamab combination led to an overall response rate (ORR) of 100 percent and a complete response (CR) rate of 87 percent in...

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

Genmab A/S (Nasdaq: GMAB): Preliminary analyses from the EPCORE® CLL-1 trial demonstrates overall response rate (ORR) of 61 percent and complete response (CR) rate of 39 percent in heavily...

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Genmab A/S (Nasdaq: GMAB): Results show 96 percent overall response rate (ORR), 87 percent complete response (CR), and 80 percent 21-month progression-free survival (PFS) in patients with...

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

  Genmab A/S (Nasdaq: GMAB): More than 20 abstracts, including four oral presentations, with new clinical data across lines of therapy and subgroups of non-Hodgkin’s lymphoma (NHL) patients New...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

GMAB - Frequently Asked Questions (FAQ)

What is the current Genmab AS share price?
The current share price of Genmab AS is US$ 19,67
How many Genmab AS shares are in issue?
Genmab AS has 660 745 350 shares in issue
What is the market cap of Genmab AS?
The market capitalisation of Genmab AS is USD 13,09B
What is the 1 year trading range for Genmab AS share price?
Genmab AS has traded in the range of US$ 0,00 to US$ 0,00 during the past year
What is the PE ratio of Genmab AS?
The price to earnings ratio of Genmab AS is 29,98
What is the cash to sales ratio of Genmab AS?
The cash to sales ratio of Genmab AS is 7,92
What is the reporting currency for Genmab AS?
Genmab AS reports financial results in DKK
What is the latest annual turnover for Genmab AS?
The latest annual turnover of Genmab AS is DKK 16,47B
What is the latest annual profit for Genmab AS?
The latest annual profit of Genmab AS is DKK 4,35B
What is the registered address of Genmab AS?
The registered address for Genmab AS is KALVEBOD BRYGGE 43, COPENHAGEN, 1260
What is the Genmab AS website address?
The website address for Genmab AS is www.genmab.com
Which industry sector does Genmab AS operate in?
Genmab AS operates in the BIOGENETIC (HUMAN) sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
TCTMTCTM Kids IT Education Inc
US$ 0,764
(321,87%)
729,72M
REBNReborn Coffee Inc
US$ 3,31
(63,05%)
55,54M
FCUVFocus Universal Inc
US$ 5,87
(56,62%)
1,73M
SOPASociety Pass Inc
US$ 1,54
(56,50%)
13,82M
CYCNCyclerion Therapeutics Inc
US$ 3,92
(54,33%)
82,39M
ENVBEnveric Biosciences Inc
US$ 2,0899
(-46,41%)
1,57M
NIVFNewGenIvf Group Ltd
US$ 0,1489
(-42,51%)
14,8M
GLSTGlobal Star Acquisition Inc
US$ 8,83
(-39,10%)
23,89k
PRPHProPhase Labs Inc
US$ 0,2633
(-38,02%)
872,46k
SPGCSacks Parente Golf Inc
US$ 0,5601
(-37,86%)
7,27M
TCTMTCTM Kids IT Education Inc
US$ 0,764
(321,87%)
731,1M
NVDANVIDIA Corporation
US$ 120,07
(-3,67%)
388,5M
RIMEAlgorhythm Holdings Inc
US$ 0,02565
(5,12%)
341,8M
CLEUChina Liberal Education Holdings Ltd
US$ 0,1938
(30,77%)
237,15M
BHATBlue Hat Interactive Entertainment Technology
US$ 0,0355
(-11,25%)
236,44M
Aucune Discussion Trouvée
Ajouter une Discussion